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trastuzumab (11 703 935 €), rituximab (9 153 856 €); in terms of DID: ifosfamid (3,43
(2004) and 6,3 (2009)), gemcitabine (4,88 (2004) and 4,66 (2009)), fluorouracil (3,14
(2004) and 2,85 (2009)). CONCLUSIONS: Financial expenditures for antineoplastic
agents are rising due to use of newand expensivemedications,which are supposed
to double within coming years and are expected to decrease one third of cancer
mortality. Senescent population with higner incidence of cancer disease is ex-
pected to slightly increase DID and medicine packages consumption.
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OBJECTIVES: Breast cancer forms in tissues of thebreast, usually inducts and lobules.
It is themost common type ofwoman‘s cancer in Slovakia (age- standardized rate- 48,
incidence rate - 2016 new cases every year, mortality rate 773 deaths annually ). The
aim of this study was to provide comparable and reliable data of utilisation of stage I
(invasive, up to 2 centimeters, no lymph nodes involved) and stage II (invasive, 2-5
centimeters, lymph nodes might be involved, over 5 centimeters- no lymph nodes
involvement) breast cancer drugs within the period 2004-2009.METHODS: Analysed
datawere abstracted fromSlovak Institute forDrugControl,which collects them from
wholesalers. Data were studied in accordance with Daily Defined Dose (DDD, with
exception of trastuzumab) and in financial units (€). RESULTS: The consumption of
drugs used in stage I and II breast cancer had increasing trend in terms of financial
burdens between 2004 and 2009 with anastrozole ( from 1 378 317 € to 1 888 478 €),,
doxorubicine (from776 400 € to 1 354 072 €),methotrexate ( from138 954 € to 650 993 €)
and trastuzumab (from 359 797 € to 11 703 935 €) decreasing trend with tamoxifen (
from261417 € to 159064 €) nadalternating trendwith cyclofosfamide ( 206156 € (2004),
223 867 € (2006), 207 042 € (2009)), epirubicine ( 238 125 € (2004), 908 690 € (2007), 629 757
€ (2009)) and fluorouracil ( 444 627 € (2004), 455 578 € (2006), 339 232 € (2009)). Highest
consumption in terms of DDD showed fluorouracil (3,24 DID (DDD/1000 inhabitants/
day) in 2006, 2007, 2008) andhighest increase ofDDDanastrazole ( 0,14DID (2004), 0,46
DID (2009)). CONCLUSIONS: Optimal treatment of breast cancer requires different
therapies. Trastuzumab is well established on Slovak market due to good reasults in
early stage treatment with few recidives. Consumption of tamoxifen and anastrozole
will be influenced by exemestane.
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OBJECTIVES: Within the framework of Chronic Myelogenous Leukaemia (CML)
treatment in Peru, and based on a previously performed economic evaluation, we
compared the costs and cost-effectiveness ratio of using 100mg/day and 140 mg/
day doses of Dasatinibwith the use of 800mg/day doses of Nilotinib or an increased
dose of Imatinib (800mg/day), for each phase of the disease, in patients who devel-
oped resistance to habitual doses of Imatinib. METHODS: A Markov model was
used for this economic evaluation, which considered a cohort of 10.000 CML pa-
tients in its three phases (chronic, accelerated and blast phase), a lifetime horizon
and a 3.5 % discount rate for costs and benefits. Model results included the costs of
each treatment alternative with Dasatinib, Nilotinib or Imatinib, and Quality Ad-
justed Life Years (QALYs) gained. Costs were measured in Peruvian SOLES of year
2010. RESULTS: In the chronic phase of the disease, dasatinib 100 mg/day yielded
the highest amount of QALYs with 6,62 and the lowest cost-effectiveness ratio. In
the accelerated phase, Dasatinib 140mg/day also showed the lowest cost-effective-
ness compared to Nilotinib and Imatinib. In the blast phase, dasatinib showed
lower cost-effectiveness ratio than imatinib.CONCLUSIONS:Dasatinib 100mg/day
showed the lowest cost-effectiveness ratios than doses of 800 mg/day of Nilotinib
and imatinib 800 mg for the treatment of patients with CML resistant to usual
imatinib doses in the chronic phase, as well as in the accelerated and blast phases.
Although there was an overall cost increase, especially due to the cost of Dasatinib
in 140 mg/day doses, this fact was explained by the increase in life years gained
and, consequently, the use of medical resources and drugs.
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OBJECTIVES: To determine the burden of bone metastases and health resource
utilisation (HRU) associated with skeletal-related events (SREs) in patients with
advanced cancer. METHODS: This observational study assessed HRU associated
with SREs (defined as spinal cord compression [SCC], surgery to bone [SB], patho-
logic fracture [PF] or radiation to bone [RB]). Patients with breast, lung or prostate
cancer metastatic to bone or multiple myeloma and life expectancy 6 months
were enrolled in centres in Germany, Italy, Spain, UK, Canada and USA after expe-
riencing a SRE. We report here the European HRU data on hospitalisation, which
were collected retrospectively for the 90 days prior to enrolment and prospectively
for approximately 18-21months. RESULTS: 631 eligible patientswith a total of 1282
SREswere enrolled across 95 European sites: 223 (35.3%) had a primary diagnosis of
breast cancer, 135 (21.4%) lung cancer, 120 (19%) prostate cancer and 153 (24.3%)
multiple myeloma. Across all tumour types, for Germany, Italy, Spain and UK,
respectively, the mean number of hospitalisations per SCC (n  91) was 0.85, 0.69,
0.53 and 1.06 with a mean length of stay (per SRE with  1 hospitalisation) of 25.6,
41.1, 34.3 and 27.7 days. For SB (n  137) mean number of hospitalisations per SRE
was 0.90, 0.76, 0.83 and 0.75 withmean stays of 19.4, 19.8, 8.4 and 10.0 days, respec-
tively. For PF (n 254),mean number of hospitalisations per SREwas 0.42, 0.49, 0.49
and 0.39 with mean stays of 18.7, 22.4, 20.2 and 20.7 days, respectively. Mean
number of hospitalisations per RB (n 692) were 0.19, 0.15, 0.16 and 0.07withmean
stays of 17.9, 16.6, 21.9 and 10.4 days respectively.CONCLUSIONS: Each SRE leads to
considerable hospitalisation, which varies by SRE type and country.
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OBJECTIVES: Use of substances (pan, chaalia, ghutka, niswar) is associated with
serious health risks. In Pakistanmost people use substances from early years of life
which keeps them on risk of short life span. It is important to understand the cost
implication and provide knowledge about the effects of these substances. The aim
of this studywas to estimate the costs of using these substances and to understand
the reasons for using substances. METHODS: This was a cross-sectional study
conducted in two residential colonies in Karachi, Pakistan during 2008 and 2009.
Pre-coded structured questionnaire was administered to collect the data on socio
demographics, costs, reasons for use of substances and use of substances per day.
The data was analyzed on SPSS version 18.0. Possible measures were taken to
ensure the confidentiality of all participants. RESULTS: From 124 randomly se-
lected residents, 107 (86%) agreed to respond. All the selected participants were
between the ages 10–71 years (meansd age 36.216.4). Of the total, about one-
fifth of the users were females. Daily use of substances was significantly higher
among males (p0.001). Further, the use was higher among adolescents than
adults (p0.001) and interestingly less educated consumed less thanhigh educated
(P0.06). Males are spending significantly higher on substances; Rs. 3711.5/day
[Rs.930 or (US$13)/month] compared to females. Overall, 41% of the cost is spent on
cigarettes followed by 27% and 23% on local and branded ghutka respectively. The
main reasons for using substances were peer pressure, easy availability of sub-
stances, stress, liking of taste and to treat toothache. CONCLUSIONS: This study
concluded that use of substances is higher among youngmales and they are spend-
ing a lot on them. To prevent this population, regular awareness campaignsmay be
held at community and school level so that, continuous re-enforcement make
them to quit from using any kind of substances.
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OBJECTIVES:Worldwide, prices for cancer drugs have been under downward pres-
sure where several governments havemandated price cuts of branded products. A
better alternative tomandated price cuts would be the estimation of a launch price
based on drug performance, cost effectiveness and a county’s ability to pay. We
developed a global pricing index for new drugs that encompasses all of these attri-
butes in patients with metastatic colorectal cancer (mCRC). METHODS: A phar-
macoeconomic model was developed to simulate clinical outcomes in mCRC pa-
tients receiving chemotherapy with the addition of a “new drug” that improves
survival by 1.4, 3 and 6 months. Cost and health state utility data were obtained
from cancer centers and oncology nurses (n112) in Canada, Spain, India, South
Africa and Malaysia. A price per dose was estimated for each survival increment
using a target value threshold of three times the per capita GDP for each country, as
recommended by the World Health Organization (WHO). Multivariable analysis
was then used to develop the pricing index, which considers survival benefit, per
capita GDP and income dispersion as measured by the Gini coefficient as predictor
variables. RESULTS: Higher survival benefits were associated with elevated drug
prices, especially in wealthier countries such as Canada. For Argentina with a per
capita GDP of $15,000 and a Gini coefficient of 51, the pricing index estimated that
for a drugwhich provides a 4month survival benefit inmCRC, the value based price
would be $U.S.630 per dose. In contrast, the same drug in a wealthier country like
Norway could command a price of $U.S.2,775. CONCLUSIONS: The application of
this index to estimate a price based on cost effectiveness would be a good starting
point for opening dialogue between the key stakeholders and a better alternative to
governments’ mandated price cuts.
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